Literature DB >> 21353793

Progesterone: the ultimate endometrial tumor suppressor.

Shujie Yang1, Kristina W Thiel, Kimberly K Leslie.   

Abstract

The uterine endometrium is exquisitely sensitive to steroid hormones that act through well-described nuclear receptors. Estrogen drives epithelial proliferation, and progesterone inhibits growth and causes cell differentiation. The importance of progesterone as a key inhibitor of carcinogenesis is reflected by the observation that women who ovulate and produce progesterone almost never get endometrial cancer. In this review we describe seminal research findings that define progesterone as the major endometrial tumor suppressor. We discuss the genes and diverse signaling pathways that are controlled by progesterone through progesterone receptors (PRs) and also the multiple factors that regulate progesterone/PR activity. By defining these progesterone-regulated factors and pathways we identify the principal therapeutic opportunities to control the growth of endometrial cancer.
Copyright © 2011. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21353793      PMCID: PMC4062362          DOI: 10.1016/j.tem.2011.01.005

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  87 in total

1.  Detection of progesterone receptor forms A and B by immunohistochemical analysis.

Authors:  P A Mote; J F Johnston; T Manninen; P Tuohimaa; C L Clarke
Journal:  J Clin Pathol       Date:  2001-08       Impact factor: 3.411

2.  The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice.

Authors:  Mei-Ling Chen; Pei-Zhang Xu; Xiao-ding Peng; William S Chen; Grace Guzman; Ximing Yang; Antonio Di Cristofano; Pier Paolo Pandolfi; Nissim Hay
Journal:  Genes Dev       Date:  2006-06-15       Impact factor: 11.361

3.  Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium.

Authors:  R L Arnett-Mansfield; A deFazio; G V Wain; R C Jaworski; K Byth; P A Mote; C L Clarke
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

4.  Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors.

Authors:  Donghai Dai; Douglas M Wolf; Elizabeth S Litman; Michael J White; Kimberly K Leslie
Journal:  Cancer Res       Date:  2002-02-01       Impact factor: 12.701

Review 5.  Mechanisms generating diversity in glucocorticoid receptor signaling.

Authors:  Javier R Revollo; John A Cidlowski
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

6.  Apparent resistance in human endometrial carcinoma during combination treatment with tamoxifen and progestin may result from desensitization following downregulation of tumor progesterone receptor.

Authors:  P G Satyaswaroop; C L Clarke; R J Zaino; R Mortel
Journal:  Cancer Lett       Date:  1992-02-29       Impact factor: 8.679

7.  Mitogen-activated protein kinase regulates nuclear association of human progesterone receptors.

Authors:  Ming Qiu; Abby Olsen; Emily Faivre; Kathryn B Horwitz; Carol A Lange
Journal:  Mol Endocrinol       Date:  2003-01-09

8.  Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.

Authors:  Charles W Whitney; Virginia L Brunetto; Richard J Zaino; Samuel S Lentz; Joel Sorosky; Deborah K Armstrong; Roger B Lee
Journal:  Gynecol Oncol       Date:  2004-01       Impact factor: 5.482

9.  Designing a schedule of progestin administration in the control of endometrial carcinoma growth in the nude mouse model.

Authors:  R Mortel; R J Zaino; P G Satyaswaroop
Journal:  Am J Obstet Gynecol       Date:  1990-04       Impact factor: 8.661

Review 10.  The steroid and thyroid hormone receptor superfamily.

Authors:  R M Evans
Journal:  Science       Date:  1988-05-13       Impact factor: 47.728

View more
  63 in total

1.  Endometrial cancer.

Authors:  Kimberly K Leslie; Kristina W Thiel; Michael J Goodheart; Koen De Geest; Yichen Jia; Shujie Yang
Journal:  Obstet Gynecol Clin North Am       Date:  2012-06       Impact factor: 2.844

Review 2.  Estrogen receptors and human disease: an update.

Authors:  Katherine A Burns; Kenneth S Korach
Journal:  Arch Toxicol       Date:  2012-05-31       Impact factor: 5.153

3.  Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.

Authors:  Henry D Reyes; Matthew J Carlson; Eric J Devor; Yuping Zhang; Kristina W Thiel; Megan I Samuelson; Megan McDonald; Shujie Yang; Jean-Marie Stephan; Erica C Savage; Donghai Dai; Michael J Goodheart; Kimberly K Leslie
Journal:  Gynecol Oncol       Date:  2015-10-30       Impact factor: 5.482

Review 4.  Endometriosis and nuclear receptors.

Authors:  Bahar D Yilmaz; Serdar E Bulun
Journal:  Hum Reprod Update       Date:  2019-07-01       Impact factor: 15.610

5.  Epigenetic modification restores functional PR expression in endometrial cancer cells.

Authors:  Shujie Yang; Xue Xiao; Yichen Jia; Xiaoyue Liu; Yuping Zhang; Xinjun Wang; Christopher J Winters; Eric J Devor; Xiangbing Meng; Kristina W Thiel; Kimberly K Leslie
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 6.  Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysis.

Authors:  Yun Fu; Zhigang Zhuang
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

Review 7.  Progesterone action in breast, uterine, and ovarian cancers.

Authors:  Caroline H Diep; Andrea R Daniel; Laura J Mauro; Todd P Knutson; Carol A Lange
Journal:  J Mol Endocrinol       Date:  2015-01-13       Impact factor: 5.098

8.  Progesterone signaling inhibits cervical carcinogenesis in mice.

Authors:  Young A Yoo; Jieun Son; Fabiola F Mehta; Francesco J DeMayo; John P Lydon; Sang-Hyuk Chung
Journal:  Am J Pathol       Date:  2013-09-05       Impact factor: 4.307

9.  Panobinostat Enhances Growth Suppressive Effects of Progestin on Endometrial Carcinoma by Increasing Progesterone Receptor and Mitogen-Inducible Gene-6.

Authors:  Hirofumi Ando; Tsutomu Miyamoto; Hiroyasu Kashima; Shotaro Higuchi; Koichi Ida; David Hamisi Mvunta; Tanri Shiozawa
Journal:  Horm Cancer       Date:  2017-05-17       Impact factor: 3.869

10.  Response-specific progestin resistance in a newly characterized Ishikawa human endometrial cancer subcell line resulting from long-term exposure to medroxyprogesterone acetate.

Authors:  Shunjun Zhao; Genxia Li; Li Yang; Lei Li; Hongyu Li
Journal:  Oncol Lett       Date:  2012-10-17       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.